A new program to ensure antibiotics are used properly, funded by the Agency for Healthcare Research and Quality (AHRQ), was associated with declines in antibiotic prescribing in ambulatory clinics even in the face of COVID-19 related disruptions, according to results presented at IDWeek.
IDSA Foundation, in collaboration with JLABS, recently awarded more than $17,000 in funding through the 2021 IDea Incubator competition to three finalists for their promising innovations aimed at advancing the field of infectious diseases.
Five new members join Board of Directors to continue the fight against COVID-19 and promote the value of ID specialists. IDSA is pleased to announce Daniel P. McQuillen, MD, FIDSA, as the society’s new president beginning Oct. 4.
IDSA and its HIVMA support the Biden Administration’s call for new global commitments to control the COVID-19 pandemic and applaud the Administration’s initial steps of donating vaccine doses and making financial contributions to COVAX, the COVID-19 Vaccines Global Access initiative.
IDSA is encouraged by today’s announcement from the Biden Administration on the allocation of more than $2 billion of American Rescue Plan funds to support infection prevention and efforts to combat antimicrobial resistance.
IDSA has expressed support for several proposed revisions to The Joint Commission’s antibiotic stewardship requirements for hospitals, while also providing additional recommendations to ensure the changes align with the Society’s strategic priorities.
IDSA supports President Biden’s multi-pronged approach to boost vaccination rates and strengthen our COVID-19 response. With COVID-19 cases on the rise and health systems stretched to capacity, it is imperative to public health and safety that eligible people get vaccinated.
IDSA is urging school systems nationwide to use all available public health tools and strategies to prevent COVID-19 transmission in schools as teachers and students return to in-person learning.
The FDA’s full approval of the Pfizer-BioNTech COVID-19 vaccine marks a pivotal milestone in the nation’s quest to control the effects of this pandemic. This approval is the culmination of intense, collaborative scientific research. The FDA’s announcement gives people who have not yet taken the vaccine additional assurance that this vaccine is safe and effective.
IDSA appreciates that HHS is planning to provide vaccinated people with a supplemental dose of vaccines if the FDA and CDC recommend a supplemental dose following a thorough and transparent evaluation of the evidence.
IDSA supports the FDA and CDC’s decision to authorize a supplemental vaccine dose for immunocompromised patients. This authorization will provide more protection for those who are at risk of serious COVID-19 illness and disease.
Increasing confidence in COVID-19 vaccines and uptake in these communities requires a creative, flexible and nimble approach that addresses the diverse concerns and barriers to vaccine access that people may have, according to a new article in Open Forum Infectious Diseases.